**Supplementary Figure S2**

Characterization of the anti-tumor effects of selective KRAS G12C inhibitor adagrasib in the H23 (**A**) and the LU65 (**B–E**) brain tumor model *in vivo.* **A.** CSF PK. Adagrasib 100 mg/kg BID was administered to non-tumor-bearing mice (n=3) for 3 days; CSF was collected 6 hours after the last dose. **B-D,** Bioluminescence imaging based evaluation of tumor volume change during and after treatment. **B.** Total flux mid/pre-ratio. **C.** Total flux pre/mid/post-treatment. **D.** Total flux ratio mid/pre, post/pre, post/mid. **E.** % body weight change over time, during and after treatment. For statistical analysis, the Mann-Whitney test was used to compare two groups, and one-way ANOVA with Tukey’s multiple comparison test for three groups. \*p≤0.05; \*\*p≤0.01; \*\*\*p≤0.001; \*\*\*\*p≤0.0001.

**A B**



**BLI: Vehicle, adagrasib**

**(Mid/Pre ratio)**

Vehicle Adagrasib

**CSF PK (Adagrasib)**

****

**C**



**BLI; Adagrasib at each timepoint**

**D**



**BLI: Adagrasib**

**(Mid/Pre, Post/Pre, Post/Mid ratio)**

**E**



Adagrasib